Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel

References

• Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J. Clin.55, 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J. Urol.166, 1611–1623 (2001).
   PubMed Web of Science ®Google Scholar
• Linehan WM, Walther MM, Zbar B. The genetic basis of cancer of the kidney. J. Urol.170, 2163–2172 (2003).
   PubMed Web of Science ®Google Scholar
• Storkel S, Eble JN, Adlakha K et al. Classification of renal cell carcinoma: workgroup n°1. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer80, 987–989 (1997).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol.163, 408–417 (2000).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17, 2530–2540 (1999).
   PubMed Web of Science ®Google Scholar
• Medical Research Council Renal Cancer Collaborators. Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet353, 14–17 (1999).
   PubMed Web of Science ®Google Scholar
• Pyrhönen S, Salminen E, Ruutu M et al. Prospective randomized trial of interferon α-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J. Clin. Oncol.17, 2859–2867 (1999).
   PubMed Web of Science ®Google Scholar
• Mickisch GHJ, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet358, 966–970 (2001).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N. Engl. J. Med.345, 1655–1659 (2001).
   PubMed Web of Science ®Google Scholar
• Flanigan RC, Mickisch G, Sylvester R, Tangen C, van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol.171, 1071–1076 (2004).
   PubMed Web of Science ®Google Scholar
• Négrier S, Escudier B, Lasset C et al. Recombinant human interleukine-2, recombinant human interferon α-2a, or both in metastatic renal cell carcinoma. N. Engl. J. Med.338, 1272–1278 (1998).
   PubMed Web of Science ®Google Scholar
• Négrier S, Pérol D, Ravaud A et al. Is intravenous IL2 superior to subcutaneous IL2 in good prognosis patients with metastatic renal cell carcinoma receiving a combination of IL2 and α-interferon? Results of the prospective randomized PERCY Duo trial. Proc. Am. Soc. Clin. Oncol.24, S225 (2006) (Abstract 4536).
   Google Scholar
• Négrier S, Pérol D, Ravaud A et al. Do cytokines improve survival in patients with metastatic renal cell carcinoma of intermediate prognosis? Results of the prospective randomized PERCY Quattro trial. Proc. Am. Soc. Clin. Oncol.23, S1093 (2005) (Abstract 4511).
   Google Scholar
• Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol.21, 3127–3132 (2003).
   PubMed Web of Science ®Google Scholar
• McDermott DF, Regan MM, Clark JI et al. Randomized Phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol.23, 133–141 (2005).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bacik J, Murphy BA, Russo RP, Mazumdar M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol.20, 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Négrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie. Ann. Oncol.13, 1460–1468 (2002).
   PubMed Web of Science ®Google Scholar
• Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res.9, 802–811 (2003).
   PubMed Web of Science ®Google Scholar
• Négrier S, Pérol D, Ménétrier-Caux C et al. Interleukin-6, interleukin-10 and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6. J. Clin. Oncol.22, 2371–2378 (2004).
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Négrier S, Elson P. Prognostic factors in patients with advanced renal cell carcinoma: development of an International Kidney Cancer Working Group. Clin. Cancer Res.10, S6310–S6314 (2004).
   Google Scholar
• Rathmell WK, Wright TM, Rini BI. Molecularly targeted therapy in renal cell carcinoma. Expert Rev. Anticancer Ther.5, 1031–1040 (2005).
   PubMed Web of Science ®Google Scholar
• Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 2505–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Escudier B, Szczylik C, Eisen T et al. Randomized Phase III trial of the Raf kinase and VEGF inhibitor sorafenib (BAY 43–9006) in patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol.23, 1093S (2005) (Abstract 4510).
   Google Scholar
• Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol.24, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, Bukowski RM et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA295, 2516–2524 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-α (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol.24, S930 (2006) (Abstract LBA3).
   Google Scholar
• Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med.349, 427–434 (2003).
   PubMed Web of Science ®Google Scholar
• Hudson CC, Liu M, Chiang GG et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol.22, 7004–7014 (2002).
   PubMed Web of Science ®Google Scholar
• Skotnicki JS, Leone CL, Smith AL. Design, synthesis, and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779. Clin. Cancer Res.7, S3749–S3750 (2001).
   Google Scholar
• Atkins MB, Hidalgo M, Stadler WM et al. Randomized Phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol.22, 909–918 (2004).
   PubMed Web of Science ®Google Scholar
• Hudes G, Carducci M, Tomczak P et al. A Phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-α (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol.24, S930 (2006) (Abstract LBA4).
   Google Scholar
• Amato RJ, Misellati A, Khan M, Chiang S. A Phase II trial of RAD001 in patients with metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol.24, S224 (2006) (Abstract 4530).
   Google Scholar
• Motzer RJ, Amato R, Todd M et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest. New Drugs21, 99–101 (2003).
   PubMed Web of Science ®Google Scholar
• Drucker B, Bacik J, Ginsberg M et al. Phase II trial of ZD1839 in patients with advanced renal cell carcinoma. Invest. New Drugs21, 341–345 (2003).
   PubMed Web of Science ®Google Scholar
• Dawson NA, Guo C, Zak R et al. A Phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin. Cancer Res.10, 7812–7819 (2004).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J. Clin. Oncol.22, 3003–3015 (2004).
   PubMed Web of Science ®Google Scholar
• Beeram M, Rowinsky EK, Weiss GR et al. Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma: a Phase II, pharmacokinetic and biological correlative study with FDG-PET imaging. Proc. Am. Soc. Clin. Oncol.22, S207 (2004) (Abstract 3050).
   Google Scholar
• Ravaud A, Gardner J, Hawkins R et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a Phase III trial in advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol.24, S217 (2006) (Abstract 4502).
   Google Scholar
• Azad NS, Posadas EM, Kwitkowski E et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. Proc. Am. Soc. Clin. Oncol.24, S121 (2006) (Abstract 3004).
   Google Scholar
• Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with combination of bevacizumab and erlotinib. J. Clin. Oncol.23, 7889–7896 (2005).
   PubMed Web of Science ®Google Scholar
• Bukowski RM, Kabbinavar F, Giglin RA et al. Bevacizumab with or without relotinib in metastatic renal cell carcinoma. Proc. Am. Soc. Clin. Oncol.24, S222 (2006) (Abstract 4523).
   Google Scholar